Professor Wandless has taken emeritus status as of 1 February 2026, and his lab is no longer active. He can be reached at wandless@stanford.edu.
If you seek reagents associated with the destabilizing domains, most constructs can be found at Addgene, and Shield-1 is available from Cheminpharma.
The destabilizing domain technology is currently being used by Obsidian Therapeutics to treat cancer patients using regulated tumor-infiltrating lymphocytes.
The lab concentrates on the invention of molecules and techniques that enable better studies of biological processes.
In short, we invent tools for biology and we are motivated by approaches that enable entirely new experiments with unprecedented control. These new techniques may also provide a window into mechanisms that cells use to maintain protein homeostasis. Protein quality control is a particular interest at present.
Learn More »